# Bausch & Lomb Corp: overview

BLCO · NYSE · CIK 1860742 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/blco.md) · [Financials](/companies/blco/financials.md) · [Filings](/companies/blco/filings.md) · [Insiders](/companies/blco/insiders.md)

Latest reported revenue: [$1.38bn](/filings/0001860742-26-000111.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 28, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001860742-26-000111).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,280 d](/filings/0001860742-26-000007.md) | [1,137](/filings/0001860742-26-000062.md) | [1,278](/filings/0001860742-26-000088.md) | [1,281](/filings/0001860742-26-000111.md) | [1,405 d](/filings/0001860742-26-000007.md) | [1,244](/filings/0001860742-26-000062.md) | [1,394](/filings/0001860742-26-000088.md) | [1,375](/filings/0001860742-26-000111.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [6.8% d](/filings/0001860742-26-000007.md) | [(7.3%)](/filings/0001860742-26-000062.md) | [(0.9%)](/filings/0001860742-26-000088.md) | [7.4%](/filings/0001860742-26-000111.md) | [8.0% d](/filings/0001860742-26-000007.md) | [2.7%](/filings/0001860742-26-000062.md) | [6.0%](/filings/0001860742-26-000088.md) | [11.3%](/filings/0001860742-26-000111.md) |
| Net margin | % | [(0.2%) d](/filings/0001860742-26-000007.md) | [(18.6%)](/filings/0001860742-26-000062.md) | [(4.9%)](/filings/0001860742-26-000088.md) | [(2.2%)](/filings/0001860742-26-000111.md) | [(4.1%) d](/filings/0001860742-26-000007.md) | [(5.7%)](/filings/0001860742-26-000062.md) | [(1.0%)](/filings/0001860742-26-000088.md) | [2.3%](/filings/0001860742-26-000111.md) |
| Diluted EPS | $ per share | not reported | [(0.60)](/filings/0001860742-26-000062.md) | [(0.18)](/filings/0001860742-26-000088.md) | [(0.08)](/filings/0001860742-26-000111.md) | not reported | [(0.20)](/filings/0001860742-26-000062.md) | [(0.04)](/filings/0001860742-26-000088.md) | [0.09](/filings/0001860742-26-000111.md) |
| Free cash flow | $m | [(70.0) d](/filings/0001860742-26-000007.md) | [(135)](/filings/0001860742-26-000062.md) | [(54.0) d](/filings/0001860742-26-000088.md) | [63.0 d](/filings/0001860742-26-000111.md) | [60.0 d](/filings/0001860742-26-000007.md) | [(68.0)](/filings/0001860742-26-000062.md) | [82.0 d](/filings/0001860742-26-000088.md) | [178 d](/filings/0001860742-26-000111.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,765](/filings/0001860742-24-000004.md) | [3,768](/filings/0001860742-25-000004.md) | [4,146](/filings/0001860742-26-000007.md) | [4,791](/filings/0001860742-26-000007.md) | [5,101](/filings/0001860742-26-000007.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [8.7%](/filings/0001860742-24-000004.md) | [5.5%](/filings/0001860742-25-000004.md) | [3.1%](/filings/0001860742-26-000007.md) | [3.4%](/filings/0001860742-26-000007.md) | [2.2%](/filings/0001860742-26-000007.md) |
| Net margin | % | [4.8%](/filings/0001860742-24-000004.md) | [0.2%](/filings/0001860742-25-000004.md) | [(6.3%)](/filings/0001860742-26-000007.md) | [(6.6%)](/filings/0001860742-26-000007.md) | [(7.1%)](/filings/0001860742-26-000007.md) |
| Diluted EPS | $ per share | [0.52](/filings/0001860742-24-000004.md) | [0.02](/filings/0001860742-25-000004.md) | [(0.74)](/filings/0001860742-26-000007.md) | [(0.90)](/filings/0001860742-26-000007.md) | [(1.02)](/filings/0001860742-26-000007.md) |
| Free cash flow | $m | [680](/filings/0001860742-24-000004.md) | [170](/filings/0001860742-25-000004.md) | [(198)](/filings/0001860742-26-000007.md) | [(59.0)](/filings/0001860742-26-000007.md) | [(66.0)](/filings/0001860742-26-000007.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/blco/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2022-06-01 | [Bausch Health Companies Inc.](/insiders/885590.md) | 10% owner | Sale (S) | 4,550,357 | $17.055 | $77.6m | [Form 4](/filings/0000899243-22-020663.md) |
| 2022-05-10 | [Bausch Health Companies Inc.](/insiders/885590.md) | 10% owner | Sale (S) | 35,000,000 | $17.055 | $596.9m | [Form 4](/filings/0000899243-22-017761.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ICAHN CARL C](/funds/921669.md) | 2026-06-30 | $58.0m | 3,500,000 |  | Unchanged |
| [OAKTREE CAPITAL MANAGEMENT LP](/funds/949509.md) | 2026-06-30 | $57.0m | 3,441,042 |  | Added +58,303 |
| [DEUTSCHE BANK AG\\](/funds/948046.md) | 2026-06-30 | $56.7m | 3,423,046 |  | Reduced −105,395 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $55.0m | 3,323,021 |  | Added +171,854 |
| [Davidson Kempner Capital Management LP](/funds/1595082.md) | 2026-06-30 | $52.3m | 3,158,972 |  | Added +959,800 |
| [GOLDENTREE ASSET MANAGEMENT LP](/funds/1278951.md) | 2026-06-30 | $44.0m | 2,660,508 |  | Unchanged |
| [CASPIAN CAPITAL LP](/funds/1518999.md) | 2026-06-30 | $33.1m | 1,999,043 |  | Unchanged |
| [GLENVIEW CAPITAL MANAGEMENT, LLC](/funds/1138995.md) | 2026-06-30 | $31.8m | 1,918,148 |  | Added +7,652 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $22.6m | 1,364,980 |  | Added +382,918 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $16.4m | 987,730 |  | Added +282,509 |

## Recent filings

[All 362 filings](/companies/blco/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 16:39 ET | [8-K](/filings/0001193125-26-436254.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-436254 |
| 2026-10-28 | 16:25 ET | [10-Q](/filings/0001860742-26-000111.md) | Quarterly report, period 2026-09-30 | 0001860742-26-000111 |
| 2026-10-28 | 07:03 ET | [8-K](/filings/0001860742-26-000108.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001860742-26-000108 |
| 2026-10-13 | 06:09 ET | [8-K](/filings/0000950103-26-015460.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950103-26-015460 |
| 2026-08-12 | 07:01 ET | [8-K/A](/filings/0000950103-26-012223.md) | 5.02 Departure or appointment of officers or directors | 0000950103-26-012223 |
| 2026-08-06 | 07:10 ET | [8-K](/filings/0000950103-26-011979.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950103-26-011979 |
| 2026-07-29 | 16:17 ET | [10-Q](/filings/0001860742-26-000088.md) | Quarterly report, period 2026-06-30 | 0001860742-26-000088 |
| 2026-07-29 | 07:02 ET | [8-K](/filings/0001860742-26-000086.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001860742-26-000086 |
| 2026-05-20 | 16:32 ET | [8-K](/filings/0001193125-26-232712.md) | 5.07 Shareholder vote results | 0001193125-26-232712 |
| 2026-04-29 | 16:36 ET | [10-Q](/filings/0001860742-26-000062.md) | Quarterly report, period 2026-03-31 | 0001860742-26-000062 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001860742-26-000007.md), filed Feb 18, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/f0a67d45-acc1-4d8e-9683-a7b5c08b9a48)

## About the filer

- CIK: 1860742
- Tickers: BLCO
- Exchange: NYSE
- SIC code: 3851 Ophthalmic Goods
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:28 ET. No prices; not investment advice.